Skip to main content Skip to navigation
Anti-Cytokeratin Purified
Down Arrow Up Arrow

Cytokeratin-7/-8; CK-7/CK-8;
Mouse BALB/c IgG2a
Human HT29 colorectal carcinoma cell line
25 μg/mL
100 μL
Phosphate buffered saline with gelatin and 0.1% sodium azide.

Preparation and Storage

1. For in vitro diagnostic use.

2. Store the reagent at 2°C to 8°C to maintain stability. Do not use after the expiration date shown on the label.

3. Do not freeze the reagent or expose it to direct light during storage or during incubation with cells. Keep the reagent vial dry.

4. Do not use the reagent if you observe any changes in appearance. Precipitation or discoloration indicates instability or deterioration.

5. The antibody reagent contains sodium azide as a preservative; however, care should be taken to avoid microbial contamination, which may cause erroneous results.

349205 Rev. 1
Down Arrow Up Arrow

The Becton Dickinson Immunocytometry Systems (BDIS) Anti-Cytokeratin (CAM 5.2) reagent is a murine monoclonal antibody used for qualitative identification of normal cells and malignant cells of epithelial origin in tissue sections (paraffin and frozen) and cytocentrifuge preparations. The clinical interpretation of any staining or its absence should be complemented by morphological studies and proper controls (such as positive, negative, and isotype-matched controls). All tests should be performed by a qualified individual.

349205 Rev. 1
Down Arrow Up Arrow
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
349205 Rev.1
Down Arrow Up Arrow

Development References (11)

  1. A National Committee for Clinical Laboratory Standards. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture (H3-A3). 1991. (Biology).
  2. Cooper D, Schermer A, Sun TT. Biology of disease classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications and limitations. Lab Invest. 1985; 52:243-256. (Biology). View Reference
  3. Gatter K, Ralfkiaer E, Skinner J, et al. An immunochemical study of malignant melanoma and its differential diagnosis from other malignant tumors. J Clin Path. 1985; 38:1353-1357. (Biology).
  4. Makin C, Bobrow L, Bodmer W. Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol. 1984; 37(9):975-983. (Biology). View Reference
  5. Moll R, Franke W, Schiller D, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors, and cultured cells. Cell. 1982; 31:11-24. (Biology). View Reference
  6. National Committee for Clinical Laboratory Standards. Protection of Laboratory Workers from Infectious Disease Transmitted by Blood, Body Fluids, and Tissue: Tentative Guideline (M29-T2). 1991. (Biology).
  7. Robbins SL, Cotran RS, Kumar V. Pathologic Basis of Disease. 1984. (Biology).
  8. Rose N, Friedman H, JL F, eds.
  9. Smedts F, Ramaekers F, Robben H, et al. Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia. Am J Pathol. 1990; 136(3):657-668. (Biology). View Reference
  10. Theaker J, Gatter K, Esiri M, et al. Epithelial membrane antigen and cytokeratin expression by meningiomas: an immunohistochemical study. J Clin Pathol. 1986; 39:435-439. (Biology).
  11. Wood GS, Warnke RA. Suppression of endogenous avidin-binding activity and its relevance to biotin-avidin detection systems. J Histochem Cytochem. 1981; 29:1196. (Biology).
すべて表示する (11) 表示項目を減らす
349205 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.